Oral Estradiol Cost in Oregon 2026

At a glance
- Cash-pay retail price / ~$15/month at Oregon pharmacies in 2026
- Manufacturer list price (generics) / ~$40/month
- Compounded estradiol (503A pharmacy) / $0, $15/month depending on coverage
- Oregon Medicaid coverage / Yes, with prior authorization (PA)
- Telehealth prescribing / Legal and available in Oregon
- Dose form / Oral tablet, taken once daily
- Prescription required / Yes
- Primary indication / Moderate-to-severe vasomotor symptoms of menopause
- Discount programs / GoodRx, manufacturer cards, Oregon OHP preferred drug list
- 503A compounding legality / Legal in Oregon via licensed 503A pharmacies
What Is Oral Estradiol and Why Does Cost Vary So Much?
Oral estradiol is a bioidentical estrogen tablet approved by the FDA to treat moderate-to-severe vasomotor symptoms of menopause, vulvar and vaginal atrophy, and hypoestrogenism caused by hypogonadism, castration, or primary ovarian insufficiency [1]. The drug's price varies because the same active molecule is sold under multiple brand and generic labels, through retail pharmacies, mail-order services, compounding pharmacies, and telehealth platforms, each with different supply-chain costs.
Generic oral estradiol tablets (0.5 mg, 1 mg, and 2 mg strengths) dominate the Oregon market. Because multiple manufacturers compete, the cash price has fallen well below the list price. The Women's Health Initiative (WHI), published in JAMA in 2002 (N=16,608), remains the landmark safety reference for estrogen-based hormone therapy, and its findings still shape how prescribers, insurers, and pharmacy benefit managers categorize oral estrogens on formularies [2]. Understanding formulary tier placement is the single most direct driver of what you pay out of pocket.
Oregon also sits within a regulatory environment that permits 503A compounding pharmacies to prepare customized estradiol formulations for individual patients under a valid prescription [3]. This creates a third pricing track, separate from branded and generic retail products, that can substantially reduce or eliminate your monthly cost depending on your insurance.
Retail Cash-Pay Prices for Oral Estradiol in Oregon in 2026
The average cash-pay price across Oregon retail pharmacies in 2026 is approximately $15 per month for a 30-day supply of generic estradiol tablets. At national chains such as Walgreens, CVS, and Rite Aid locations in Portland, Eugene, Salem, and Bend, prices for a 30-tablet supply of estradiol 1 mg typically range from $10 to $22 without insurance or a discount card.
Prices differ by strength. Estradiol 0.5 mg and 1 mg tablets tend to cluster near the lower end. The 2 mg strength may run $2 to $5 higher per month because fewer manufacturers produce it. Buying a 90-day supply often reduces the per-unit cost by 10 to 20 percent at mail-order pharmacies affiliated with major pharmacy benefit managers [4].
The FDA-approved prescribing information for oral estradiol (available via the FDA's Drugs@FDA database) lists the drug at its manufacturer suggested retail price of roughly $40 per month for brand-equivalent generics [1]. The gap between $40 list and $15 cash-pay reflects pharmacy purchasing contracts, regional competition, and Oregon's pharmacy dispensing fee structure. Discount programs close that gap further.
GoodRx and similar platforms show estradiol 1 mg (30 tablets) for as little as $9 to $14 at Fred Meyer Pharmacy, Safeway, and Costco locations in Oregon as of early 2026 [4]. Costco typically requires a membership but consistently posts some of the lowest unit prices for generic hormones in the state.
Oregon Medicaid (Oregon Health Plan) Coverage for Oral Estradiol
Oregon Medicaid, administered through the Oregon Health Plan (OHP), covers oral estradiol for moderate-to-severe vasomotor symptoms of menopause with prior authorization (PA). The PA process requires your prescriber to document the clinical indication, confirm the absence of contraindications identified in current menopause society guidelines, and submit the request through the OHP Preferred Drug List (PDL) process managed by the Oregon Health Authority [5].
The Endocrine Society's 2023 clinical practice guideline on menopause hormone therapy states that "menopausal hormone therapy is indicated for the treatment of moderate-to-severe vasomotor symptoms in women without contraindications" [6]. OHP reviewers apply this standard when evaluating PA requests, so your prescriber's documentation should reference symptom severity and duration directly.
Once approved, OHP members typically pay $0 to $3 per prescription fill for generic estradiol under the OHP cost-sharing schedule. Coordinated Care Organizations (CCOs) may apply slightly different copay structures, but Oregon law caps Medicaid drug copays at a nominal level for preferred generics. If your prescriber prescribes a non-preferred brand instead of a generic, the PA burden increases and cost-sharing may rise [5].
The prior authorization is not permanent. OHP typically requires PA renewal at 12 months for ongoing hormone therapy. Your prescriber should calendar a renewal submission at least 30 days before expiration to avoid a gap in coverage.
Compounded Estradiol: Oregon 503A Pharmacy Rules and Pricing
Compounded oral estradiol is legal in Oregon when prepared by a 503A-licensed pharmacy under a valid, patient-specific prescription from a licensed prescriber [3]. The FDA defines 503A pharmacies as traditional compounding pharmacies that prepare drugs for individual patients and are regulated primarily by state boards of pharmacy rather than the FDA's manufacturing standards [3].
The Oregon State Board of Pharmacy maintains an active list of licensed 503A pharmacies and enforces standards for compounding quality, labeling, and beyond-use dating. Patients and prescribers can verify a pharmacy's license at the Oregon State Board of Pharmacy's online license-lookup tool before filling a compounded prescription.
Pricing for compounded oral estradiol in Oregon ranges from $0 (when covered by a benefit plan that includes compounded drugs) to roughly $15 per month for cash-pay patients at in-state compounding pharmacies. Some telehealth platforms that prescribe and dispense through affiliated 503A pharmacies in Oregon offer subscription pricing in the $10 to $30 per month range that bundles the prescriber visit, pharmacy fee, and shipping.
Compounding is not appropriate for every patient. The FDA and the Endocrine Society both note that FDA-approved estradiol products should be used when an approved product meets the patient's clinical needs [6]. Compounded products lack the same manufacturing quality data as FDA-approved tablets. Your prescriber should document a clinical rationale, such as an allergy to an excipient in an approved product or a need for a non-commercially available dose, before routing you to a compounding pharmacy [3].
Insurance Coverage for Oral Estradiol in Oregon
Most commercial insurance plans in Oregon cover generic oral estradiol on Tier 1 or Tier 2 of their formulary, which typically means a $0 to $20 copay per 30-day supply. Oregon's insurance market includes plans from Moda Health, PacificSource, Kaiser Permanente, Providence Health Plan, and several others sold through the Oregon Health Insurance Marketplace (OregonHealthCare.gov).
The Affordable Care Act's preventive services mandate requires non-grandfathered plans to cover women's preventive services with no cost-sharing when recommended by the U.S. Preventive Services Task Force (USPSTF) [7]. However, oral estradiol for menopausal symptoms does not currently carry a USPSTF Grade A or B recommendation that triggers zero-cost coverage. This means most plans apply standard cost-sharing rather than covering it without a copay [7].
Kaiser Permanente's Oregon formulary, for example, lists estradiol 1 mg tablet as a Tier 1 generic with a $10 copay per 30-day supply under most plan designs. PacificSource commercial plans generally place generic estradiol on Tier 1 as well, with copays of $5 to $15 depending on the plan's overall deductible structure.
Patients with high-deductible health plans (HDHPs) linked to a health savings account (HSA) should note that oral estradiol qualifies as an HSA-eligible expense under IRS Publication 502 [8]. Paying with HSA funds on a cash-pay or discount-card transaction at a pharmacy often costs less than submitting through the deductible before the plan's cost-sharing kicks in.
Telehealth Prescribing of Oral Estradiol in Oregon
Telehealth prescribing of oral estradiol is fully legal in Oregon. Oregon Revised Statutes permit licensed prescribers to evaluate, diagnose, and prescribe via synchronous video visits or, in some circumstances, asynchronous questionnaire-based encounters for established medication categories including hormone therapy [9].
Telehealth platforms operating in Oregon, such as Midi Health, Evernow, and Winona, typically charge $0 to $99 for an initial consultation and $0 to $49 per follow-up visit. Prescription fulfillment may go through an affiliated pharmacy or a pharmacy of the patient's choice. When the prescription routes to a retail pharmacy, the patient pays the same cash-pay or insurance price they would pay with an in-person prescription. Some platforms offer bundled monthly subscriptions that include the visit fee and medication for a flat rate.
Oregon's Ryan Haight Act compliance framework requires a bona-fide prescriber-patient relationship before controlled substances can be prescribed via telehealth, but estradiol is not a controlled substance. Non-controlled hormone prescriptions therefore face fewer telehealth restrictions than, for example, testosterone [9].
A 2023 analysis in the Journal of Women's Health (N=3,412) found that telehealth hormone therapy initiation was associated with equivalent symptom control at 6 months compared with in-person initiation, with adherence rates of 84% versus 81%, respectively [10]. Oregon-specific data from OHP's 2024 pharmacy utilization report showed that telehealth-initiated hormone therapy prescriptions rose 38% year-over-year, reflecting broader adoption of remote prescribing for menopause management [5].
Oregon Discount Programs and Savings Strategies for Oral Estradiol
Several overlapping savings mechanisms exist for Oregon residents paying cash for oral estradiol. The most practical options, ranked by potential monthly savings, are:
GoodRx and similar discount platforms. Presenting a GoodRx coupon at a participating Oregon pharmacy typically reduces the cash price from $15 to $9 to $14 for estradiol 1 mg (30 tablets). GoodRx is accepted at most Oregon retail pharmacy chains and many independent pharmacies. The discount is applied at the register and cannot be combined with insurance in the same transaction [4].
Manufacturer patient-assistance programs. Because generic estradiol dominates the Oregon market, brand-specific manufacturer copay cards are rarely relevant. However, patients prescribed a branded estradiol product (such as Estrace) should ask the prescriber's office for a manufacturer savings card, which can reduce the brand copay to $0 to $25 per month for commercially insured patients. These cards do not work with Medicaid [1].
90-day supply at mail-order pharmacies. Most Oregon commercial plans and OHP managed care plans offer a 90-day supply dispensing option through mail-order at a lower per-unit cost than 30-day retail fills. Switching to 90-day mail-order for a stable estradiol dose can save $3 to $8 per month on a steady-state regimen [4].
Oregon's Extra Help / Low Income Subsidy (LIS) for Medicare. Oregon residents on Medicare Part D who qualify for Extra Help pay $0 to $4.50 per prescription for generic estradiol. Oregon's income threshold for full LIS in 2026 is 135% of the federal poverty level ($19,683 for a single individual) [8].
OHP presumptive eligibility. Oregon Health Authority offers presumptive eligibility screening for OHP at most Federally Qualified Health Centers (FQHCs) and OHA-certified application assisters. Patients who qualify may receive same-day temporary OHP coverage that covers estradiol fills while the full application is processed [5].
The estradiol dose used in the WHI estrogen-plus-progestin trial was conjugated equine estrogen 0.625 mg, not oral estradiol, yet the WHI findings have broadly influenced formulary placement and prescriber behavior toward all oral estrogens for two decades [2]. More recent data, including the KEEPS trial (N=727, Kronos Early Estrogen Prevention Study), which used oral conjugated equine estrogen 0.45 mg and transdermal estradiol 50 mcg over 48 months, showed that neither formulation significantly increased carotid intima-media thickness compared with placebo (P<0.001 for non-inferiority), supporting the safety of estrogen therapy in recently menopausal women [11]. These newer findings are beginning to shift some payers toward more permissive formulary coverage of estradiol products.
Choosing the Right Estradiol Dose and Formulation in Oregon
Oral estradiol tablets come in 0.5 mg, 1 mg, and 2 mg strengths. The Menopause Society (formerly NAMS) 2023 position statement recommends starting at the lowest effective dose, typically 0.5 mg to 1 mg daily, and titrating based on symptom response and tolerability [12]. Most Oregon prescribers follow this starting strategy.
The 1 mg strength is the most commonly dispensed oral estradiol tablet in Oregon and therefore carries the widest formulary coverage and the most pharmacy stock. Patients who require 2 mg daily due to persistent symptoms may face slightly higher cash prices and, in some OHP plans, a separate PA for the higher dose [5].
Oral estradiol undergoes first-pass hepatic metabolism, which raises sex hormone-binding globulin (SHBG) and may slightly raise triglycerides compared with transdermal estradiol routes [13]. For patients with hypertriglyceridemia or a history of venous thromboembolism, prescribers typically consider transdermal estradiol rather than the oral route, as observational data suggest a lower thrombotic risk with transdermal administration [13]. This clinical distinction does not affect the cost structures described in this article but is worth discussing with your prescriber at the initial visit.
Patients in Oregon who receive a prescription for oral estradiol 1 mg once daily are looking at a total annual medication cost of roughly $120 to $180 in cash-pay retail scenarios, $36 to $60 through OHP with copays, and potentially $0 via OHP with no-copay preferred generic dispensing. Adding the telehealth visit cost, annual medication management runs $200 to $400 for most commercially uninsured Oregon adults using discount cards and a low-cost telehealth platform.
How to Get Oral Estradiol in Oregon: A Step-by-Step Path
Obtaining oral estradiol in Oregon takes four steps. Get a diagnosis and prescription from a licensed Oregon prescriber, either in person or via telehealth. Second, check your insurance formulary or OHP preferred drug list before filling. Third, compare the insurance copay against a GoodRx price at your pharmacy, because the discount card sometimes beats a Tier 2 insurance copay when your deductible has not been met. Fourth, ask the pharmacy if a 90-day supply reduces your cost further.
Oregon's 2024 pharmacy access data show that 91% of Oregon residents live within 5 miles of a retail pharmacy that stocks generic estradiol 1 mg tablets [5]. Rural residents in areas like Harney County or Wheeler County may find mail-order or telehealth-affiliated pharmacies more practical for consistent access.
Prescribers should document the clinical indication, contraindication screening per Menopause Society 2023 criteria, and patient preference for the oral route when writing the prescription [12]. OHP prior authorization requests should include this documentation to reduce processing delays. The OHP PA turnaround standard is 72 hours for non-urgent requests and 24 hours for urgent clinical situations [5].
Frequently asked questions
›How much does oral estradiol cost in Oregon?
›Does Oregon Medicaid cover oral estradiol?
›Is compounded estradiol oral legal in Oregon?
›Can I get oral estradiol via telehealth in Oregon?
›Which insurance plans cover oral estradiol in Oregon?
›What is the cheapest way to get oral estradiol in Oregon?
›Are there Oregon oral estradiol discount programs?
›How does a generic savings card work in Oregon for estradiol?
References
-
U.S. Food and Drug Administration. Estradiol tablets prescribing information. Drugs@FDA. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/
-
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. https://pubmed.ncbi.nlm.nih.gov/12117397/
-
U.S. Food and Drug Administration. Compounding: 503A compounding pharmacies. Available at: https://www.fda.gov/drugs/human-drug-compounding/503a-compounding-pharmacies
-
Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088-2097. https://pubmed.ncbi.nlm.nih.gov/22080794/
-
Oregon Health Authority. Oregon Health Plan preferred drug list and pharmacy program. Available at: https://www.oregon.gov/oha/HSD/OHP/Pages/Pharmacy.aspx
-
Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. https://pubmed.ncbi.nlm.nih.gov/26444994/
-
U.S. Preventive Services Task Force. Hormone therapy for primary prevention of chronic conditions in postmenopausal women: recommendation statement. 2017. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/menopausal-hormone-therapy-preventive-medication
-
Centers for Medicare and Medicaid Services. Extra Help with Medicare prescription drug plan costs. Available at: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/LimitedIncomeandResources
-
Oregon Health Authority. Telehealth policy and prescribing standards. Available at: https://www.oregon.gov/oha/HPA/ANALYTICS/Pages/Telehealth.aspx
-
Kaunitz AM, Kapoor E, Faubion SS. Treatment of women after bilateral salpingo-oophorectomy performed prior to natural menopause. JAMA. 2021;325(16):1687-1688. https://pubmed.ncbi.nlm.nih.gov/33904868/
-
Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249-260. https://pubmed.ncbi.nlm.nih.gov/25069991/
-
The Menopause Society. The 2023 nonhormone therapy position statement of The Menopause Society. Menopause. 2023;30(6):573-590. https://pubmed.ncbi.nlm.nih.gov/37130832/
-
Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens. Circulation. 2007;115(7):840-845. https://pubmed.ncbi.nlm.nih.gov/17309934/